Oncology

Patient advocacy group
#Cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Patient centricity

Patient groups issue call to action on patient-centric clinical trials

A new whitepaper has introduced the concept of ‘cross-over’ options in cancer clinical trials, as a way to make trials more patient-centric in design. ‘Cross-over arms in oncology clinical trials: An important consideration for patients’ was published by the Cholangiocarcinoma Foundation (CCF) with the aim of… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

Telomeres on chromosomes
#Cancer research #Cancer Research UK #Institute of Cancer Research #Oncology

Study identifies potential new cancer drug targets

A new study has provided insights into the biological mechanism that supports survival of hard-to-treat cancers. In the new study, led by scientists at The Institute of Cancer Research and published in Nature Communications, researchers identify a new cellular role of a protein called EXD2 nuclease… Read More

#Cancer Research #News

Peptide
#Cancer research #HBC Immunology #Oncology #Peptides #Prostate cancer #Seed funding #Tumour microenvironment (TME)

Start-up to study peptides that modulate gene expression

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism… Read More

#News #Start-up Zone

Blood cells
#Blood cancer #Bristol Myers Squibb #FDA #Oncology #Phase III trial

FDA expands Reblozyl approval to first-line use

The US Food and Drug Administration (FDA) has expanded the use of Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) to include first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes (MDS). The approval is for the treatment of anaemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult… Read More

#News #Regulatory

Breast cancer
#Arvinas #Breast cancer #Cancer research #Oncology #Pfizer #UK

ER degrader for breast cancer receives UK Innovation Passport

Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader. It is intended for the treatment of patients with oestrogen receptor (ER)+/ human epidermal growth factor receptor (HER)2- locally-advanced breast cancer or metastatic breast cancer. Read More

#News #Regulatory

MRI of the brain showing glioblastoma
#Brain cancer #Cancer research #Cancer vaccine #Immunomic Therapeutics #Oncology #Phase I trial

Plasmid DNA vaccine for brain cancer enters Phase I trial

Immunomic Therapeutics has commenced its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. ITI-1001 is an investigational plasmid DNA vaccine therapy designed to target the pp65, IE-1 and… Read More

#Cancer Research #News

Monoclonal antibody
#Alentis Therapeutics #Cancer research #FDA #Head and neck cancer #Monoclonal antibodies #Oncology

FDA fast-tracks monoclonal antibody for head and neck cancer

Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody. ALE.C04 is indicated to treat patients with recurrent or metastatic CLDN1-positive head and neck squamous cell carcinoma (HNSCC). Fast Track designation… Read More

#Editor's Choice #News #Regulatory

#Cancer research #Oncology #Partnership #United States

CancerX initiative aims to boost innovation in cancer treatment

The White House Cancer Moonshot initiative has announced a new public-private partnership to boost innovation in the fight against cancer. CancerX will be co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center. It blends DiMe’s expertise in convening cross-disciplinary groups to develop clinical-quality resources… Read More

#Cancer Research #News

#Biotech #Cell and gene therapy #Clinical trials #Market reporting #Oncology

New podcast: A deep dive into US drug discovery

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “US biotech: Focus on positive growth… Read More

#News

European Commission
#Bispecific Antibodies #EU #European Commission #Janssen #Myeloma #Oncology

“Important new approach” to myeloma now available in the EU

The European Commission (EC) has granted conditional marketing authorisation (CMA) for Janssen’s Talvey (talquetamab) as monotherapy for relapsed and refractory multiple myeloma (RRMM). It is approved in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an… Read More

#News #Regulatory

Medical laboratory
#Breast cancer #Cancer research #Evgen Pharma #Oncology #Phase I trial

Phase Ib study proves efficacy of SFX-01 coated tablet formation

Evgen Pharma has revealed the final data from its Phase Ib healthy volunteer study using the company’s new enteric coated tablet formation of its lead asset SFX-01. SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The company has already completed three trials in patients,… Read More

#Cancer Research #News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Diana Spencer has chosen news stories this week which all discuss pre-clinical research studies… Read More

#News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (14-18 August)  

News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted… Read More

#News